Trulicity Cost in Illinois (2026): Prices, Insurance, Medicaid & Savings

What Does Trulicity Actually Cost in Illinois in 2026?

The sticker price for Trulicity across Illinois retail pharmacies is $931 per month, matching Eli Lilly's national wholesale acquisition cost. That number applies to every pen strength, from the 0.75 mg starter dose to the 4.5 mg maximum. Very few patients pay this full amount. Insurance coverage, manufacturer programs, and pharmacy-level discounts shift the real out-of-pocket figure considerably lower for most people filling prescriptions in Illinois.

Dulaglutide belongs to the GLP-1 receptor agonist class, drugs that mimic the incretin hormone GLP-1 to improve glycemic control and reduce appetite. The FDA approved Trulicity in 2014 for type 2 diabetes, and later expanded its label to include cardiovascular risk reduction based on the REWIND trial [1]. Illinois ranks among the top 10 states by GLP-1 prescription volume, which means pharmacies across Chicago, Springfield, Peoria, and the collar counties stock it routinely. Availability is not the issue. Price is.

A 2023 IQVIA analysis found that GLP-1 receptor agonist spending in the United States exceeded $40 billion annually, with average per-patient costs rising faster than inflation. Illinois patients face the same pressure. The sections below break down every realistic path to a lower Trulicity cost in this state.

Illinois Medicaid Coverage for Trulicity

Illinois Medicaid, administered through the state's HealthChoice managed care plans, covers Trulicity with prior authorization. The PA requirement exists because Medicaid preferred drug lists (PDLs) typically favor the least-cost GLP-1 option first. Your prescriber will need to document that you have a diagnosis of type 2 diabetes and, in many cases, that you tried metformin or another first-line agent before stepping up to an injectable GLP-1.

The Illinois Department of Healthcare and Family Services updates its PDL quarterly. As of early 2026, dulaglutide remains accessible through Medicaid, but plan-level formulary placement can shift. Patients enrolled in Molina, Meridian, Blue Cross Community, or CountyCare should call their plan's pharmacy line to confirm the current tier and PA criteria. PA approvals in Illinois Medicaid typically take 24 to 72 hours when the prescriber submits complete documentation.

For Medicaid enrollees who receive approval, the copay is $0 to $4 per prescription depending on the managed care plan. The American Diabetes Association Standards of Care (2024) recommend GLP-1 receptor agonists as second-line therapy for patients with type 2 diabetes and established atherosclerotic cardiovascular disease or high cardiovascular risk, a recommendation that strengthens PA approval odds when documented in the request [2].

Commercial Insurance: What Illinois Plans Cover

The majority of large employer plans and ACA marketplace plans sold in Illinois include at least one GLP-1 receptor agonist on formulary. Whether that agent is Trulicity, semaglutide (Ozempic), or tirzepatide (Mounjaro) depends on the pharmacy benefit manager (PBM) negotiating on the plan's behalf. Express Scripts, CVS Caremark, and OptumRx each maintain different preferred positions for these drugs.

Here is what shapes your actual cost:

Formulary tier. Trulicity sits on Tier 3 (preferred brand) in some plans and Tier 4 (non-preferred specialty) in others. A Tier 3 placement might mean a $50 copay. Tier 4 could mean 25% to 33% coinsurance on the $931 list price, pushing your share above $230 per month before any manufacturer offset.

Step therapy. Some Illinois commercial plans require a trial of metformin, and occasionally a sulfonylurea, before approving a GLP-1. The Endocrine Society clinical practice guideline supports early GLP-1 use in patients with HbA1c above 1.5% over target or with comorbid cardiovascular disease, which can support an appeal if your plan imposes step therapy [3].

Accumulator adjustment programs. A growing number of PBMs no longer count manufacturer copay card payments toward your deductible or out-of-pocket maximum. Illinois has not passed accumulator adjustment legislation as of May 2026, so patients should verify whether their plan uses this practice.

Patients on Blue Cross Blue Shield of Illinois PPO plans, one of the largest commercial carriers in the state, generally find Trulicity on formulary at a Tier 3 position. UnitedHealthcare and Aetna plans sold through the Illinois ACA exchange vary by metal level, with Silver and Gold plans offering lower cost-sharing for preferred brands.

The Eli Lilly Trulicity Savings Card

Eli Lilly offers the Trulicity Savings Card directly to commercially insured patients. Eligible individuals may pay as little as $25 per monthly fill, with the card covering the difference between that amount and the patient's plan-determined copay or coinsurance. The card has a maximum annual benefit (historically $6,000 to $8,000 per year, though Lilly adjusts this periodically).

Key restrictions apply. The card cannot be used by patients enrolled in any government-funded program: Medicare Part D, Medicaid, TRICARE, or VA benefits. It also cannot be combined with certain copay accumulator programs where the PBM blocks manufacturer assistance from counting toward cost-sharing limits.

To activate the card in Illinois, patients visit the Lilly Trulicity website, enter their insurance information, and receive a BIN/PCN/Group number to present at the pharmacy counter. Most Illinois Walgreens, CVS, and Jewel-Osco pharmacy locations process the card at point of sale. Processing takes seconds. If the pharmacy rejects it, the most common fix is verifying that the group number was entered correctly.

Compounded Dulaglutide in Illinois: Legality and Access

Compounded dulaglutide is available in Illinois through 503A-licensed compounding pharmacies. Section 503A of the Federal Food, Drug, and Cosmetic Act permits state-licensed pharmacies to compound medications, including GLP-1 receptor agonists, when they hold a valid patient-specific prescription and comply with state Board of Pharmacy rules.

The Illinois Department of Financial and Professional Regulation (IDFPR) oversees compounding pharmacy licensure. A 503A pharmacy in Illinois can compound dulaglutide if it operates under a prescriber's order for an individual patient and sources the active pharmaceutical ingredient (API) from an FDA-registered supplier. The compound is not the same as the brand-name Trulicity pen. It is typically dispensed as a multi-dose vial requiring the patient to draw and inject the dose with a syringe.

Pricing for compounded dulaglutide varies. Some 503A pharmacies in Illinois advertise monthly costs between $150 and $350, substantially below the $931 brand list price. Patients considering this route should confirm three things: that the pharmacy holds a current Illinois compounding license, that the API source is FDA-registered, and that their prescriber is willing to write for a compounded formulation.

One clinical consideration matters here. The REWIND trial (N=9,901), which demonstrated a 12% relative risk reduction in major adverse cardiovascular events with dulaglutide 1.5 mg over a median 5.4-year follow-up, used the branded Trulicity formulation [1]. Compounded versions have not been tested in randomized trials of that scale. The ADA Standards of Care do not distinguish between branded and compounded GLP-1 products in their glycemic management recommendations, but they note that patients should use FDA-approved products when available [2].

Telehealth Prescribing of Trulicity in Illinois

Illinois permits telehealth prescribing of Trulicity. The state's Telehealth Act, updated in 2021, allows licensed prescribers to evaluate patients via audio-video visits and write prescriptions for non-controlled substances, which includes dulaglutide. No in-person visit is required for an initial Trulicity prescription in Illinois, though individual telehealth platforms may set their own clinical protocols.

Several national telehealth platforms operate in Illinois and prescribe GLP-1 receptor agonists. These visits typically cost $50 to $150 for the consultation. The prescription itself is sent electronically to the patient's chosen pharmacy. Patients using telehealth should ensure that the prescribing clinician holds an active Illinois medical license. The Illinois State Medical Board maintains a public license verification tool for confirming credentials.

Telehealth is particularly useful for patients in southern Illinois or rural downstate communities where endocrinology and obesity medicine specialists are scarce. A 2022 study in the Journal of the American Medical Association found that telehealth-initiated GLP-1 prescriptions had similar adherence rates to in-person prescriptions at 6 months, with no significant difference in HbA1c reduction [4].

Discount Programs and Pharmacy Shopping in Illinois

Beyond the Lilly savings card, several additional strategies lower Trulicity costs in Illinois.

GoodRx, RxSaver, and similar discount cards. These aggregator platforms negotiate cash-pay rates with pharmacies. Trulicity discount card prices at Illinois pharmacies fluctuate between $780 and $900, a modest savings from list price but meaningful only for uninsured patients who cannot access the manufacturer card.

Independent pharmacy pricing. Small independent pharmacies in Illinois sometimes offer slightly lower cash prices than chain pharmacies because they use different wholesaler contracts. Calling two or three pharmacies for a price check before filling the prescription is a simple step that can save $20 to $80 per month.

340B pharmacies. Federally qualified health centers (FQHCs) in Illinois participate in the 340B Drug Pricing Program and can dispense Trulicity at substantially reduced prices to eligible patients. Illinois has over 50 FQHCs across Cook County and downstate. Patients who receive primary care at an FQHC should ask whether the on-site or contract pharmacy participates in 340B pricing for GLP-1 agents.

Patient assistance programs (PAPs). Lilly Cares, the Eli Lilly patient assistance foundation, provides Trulicity at no cost to patients with household incomes at or below 400% of the federal poverty level who lack prescription drug coverage. The application requires income documentation and a prescriber signature. Processing takes 4 to 6 weeks.

Clinical Context: Why Dulaglutide Costs What It Does

Trulicity's pricing reflects both its clinical evidence base and the broader GLP-1 market dynamics. The REWIND trial randomized 9,901 adults with type 2 diabetes (mean age 66, 31% with prior cardiovascular events) to dulaglutide 1.5 mg or placebo, with a primary composite endpoint of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. Over a median 5.4 years, dulaglutide reduced this composite by 12% (HR 0.88, 95% CI 0.79 to 0.99, P=0.026) [1]. That result earned dulaglutide an expanded FDA indication for cardiovascular risk reduction.

Dr. Hertzel Gerstein, principal investigator of the REWIND trial, noted: "This is the first GLP-1 receptor agonist trial to enroll a majority of participants without established cardiovascular disease, suggesting the benefit extends to primary prevention" [1].

The AWARD trial program, comprising 11 phase III studies, established dulaglutide's glycemic efficacy. AWARD-1 (N=978) showed dulaglutide 1.5 mg reduced HbA1c by 1.51% at 26 weeks versus 0.46% for placebo [5]. AWARD-3 (N=807) demonstrated superiority over metformin monotherapy in treatment-naive patients, with HbA1c reductions of 0.78% versus 0.56% at 52 weeks (Umpierrez et al., Diabetes Care 2014) [6].

The Institute for Clinical and Economic Review (ICER) assessed GLP-1 receptor agonist value in 2023 and concluded that dulaglutide's price was "aligned with clinical benefit" relative to other agents in the class, though ICER noted that list prices across the entire GLP-1 class exceed value-based benchmarks by 40% to 60% when the drugs are used primarily for glycemic control without cardiovascular comorbidity. The Endocrine Society has called for greater PBM transparency in GLP-1 pricing, arguing that negotiated rebates often do not flow back to patients at the pharmacy counter [3].

Comparing Trulicity to Other GLP-1 Options Available in Illinois

Illinois patients prescribed a GLP-1 receptor agonist have multiple branded options. Comparing them by cost and clinical profile helps determine where dulaglutide fits.

Ozempic (semaglutide 2 mg injection). List price approximately $935 per month. The SUSTAIN-6 trial (N=3,297) showed a 26% reduction in MACE with semaglutide versus placebo over 2.1 years (Marso et al., NEJM 2016) [7]. Semaglutide generally achieves slightly greater HbA1c reduction (1.5% to 1.8%) compared to dulaglutide (1.1% to 1.5%) at maximum doses.

Mounjaro (tirzepatide). List price approximately $1,023 per month. Tirzepatide is a dual GIP/GLP-1 receptor agonist. The SURPASS-2 trial (N=1,879) demonstrated HbA1c reductions of 2.0% to 2.3% with tirzepatide versus 1.9% with semaglutide 1 mg at 40 weeks (Frias et al., NEJM 2021) [8]. Tirzepatide's cardiovascular outcomes trial (SURPASS-CVOT) is expected to report results by late 2026.

Rybelsus (oral semaglutide). List price approximately $935 per month. Oral dosing may appeal to patients who prefer not to inject, though bioavailability constraints limit the maximum effective dose.

Trulicity's advantage for Illinois patients often comes down to formulary positioning. On some commercial and Medicaid plans, dulaglutide occupies a preferred tier that Ozempic or Mounjaro does not, making it the lowest-cost branded GLP-1 for those specific enrollees. Checking your plan's formulary before assuming one drug is cheaper than another is the single most impactful cost-saving step.

Steps to Get the Lowest Trulicity Price in Illinois

A practical sequence for Illinois residents seeking to minimize out-of-pocket cost:

1. Confirm your plan's formulary tier for dulaglutide by calling the number on your insurance card or checking the plan's online drug lookup tool.
2. If you are commercially insured, activate the Eli Lilly Trulicity Savings Card before your first fill.
3. If you are on Illinois Medicaid, ask your prescriber to submit prior authorization with documentation of diagnosis, HbA1c, and prior metformin use.
4. If uninsured, apply to the Lilly Cares patient assistance program if your income qualifies, or request pricing from a 503A compounding pharmacy.
5. Compare prices at two to three pharmacies, including at least one independent or FQHC-affiliated location.
6. Consider telehealth for the prescribing visit if specialist access is limited in your area.

The difference between the highest and lowest realistic out-of-pocket cost for Trulicity in Illinois spans from $0 (Lilly Cares PAP or Medicaid with approved PA) to $931 (full cash price, no programs used). Most insured patients land between $25 and $150 per month with the savings card active.